SCHEMBL13680220

SCHEMBL13680220

COc1cc2ncnc(Oc3cccc(N)c3)c2cc1OCCN1CCN(CCO)CC1

nearest known ligand 0.62

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
RAF1 P04049 13/20 0.62
BRAF P15056 12/20 0.62
CSF1R P07333 2/20 0.54
PDGFRB P09619 2/20 0.54
FLT4 P35916 2/20 0.54
FLT3 P36888 2/20 0.54
KDR P35968 2/20 0.54
RET P07949 1/20 0.54
KIF5B P33176 1/20 0.54
AURKA O14965 1/20 0.52
EGFR P00533 2/20 0.52
LCK P06239 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19258467 0.90 AURKA (0.62) RAF1BRAFCSF1RPDGFRBFLT4
SCHEMBL13680218 0.90 BRAF (0.64) RAF1BRAFCSF1RPDGFRBFLT4
SCHEMBL1012845 0.89 BRAF (0.62) RAF1BRAFCSF1RPDGFRBFLT4
SCHEMBL19258108 0.85 KDR (0.63) RAF1BRAFCSF1RPDGFRBFLT4
SCHEMBL1015360 0.83 KDM1A (0.66) RAF1BRAFCSF1RPDGFRBFLT4
SCHEMBL1012448 0.82 KDR (0.73) RAF1BRAFCSF1RPDGFRBFLT4
SCHEMBL7211076 0.82 KDR (0.66) RAF1BRAFCSF1RPDGFRBFLT4
Ammonia Solution, Strong SCHEMBL1010619 0.82 KDM1A (0.65) RAF1BRAFCSF1RPDGFRBFLT4
SCHEMBL16692931 0.81 BRAF (0.68) RAF1BRAFCSF1RPDGFRBFLT4
SCHEMBL13680228 0.81 BRAF (0.62) RAF1BRAFKDRRETKIF5B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3147281-A1 QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF Ambit Biosciences Corporation (US) 2017-03-29 EP disclosed
EP-2947072-A1 1-(3-(6,7-DIMETHOXYQUINAZOLIN-4-YLOXY)PHENYL)-3-(5-(1,1,1-TRIFLUORO-2-METHYLPROPAN-2-YL)ISOXAZOL-3-YL)UREA AS RAF KINASE MODULATOR IN THE TREATMENT OF CANCER DISEASES Ambit Biosciences Corporation (US) 2015-11-25 EP disclosed
WO-2009117080-A1 QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATON (US) 2009-09-24 WO disclosed